Metronidazol B. Braun (Metronidazole)

Metronidazole is taken up by anaerobic cells and reduced to nitro radicals by microbial enzymes. These radicals damage DNA and inhibit nucleic acid synthesis, leading to cell death. The drug selectively targets anaerobes because aerobic cells lack the necessary reduction pathways.

The exact dose, frequency, and duration are set by the prescribing clinician based on infection type, severity, patient weight, renal and hepatic function, and local antimicrobial guidelines. No standard dose is provided here.

Safety data for metronidazole in pregnancy are limited, and the product’s pregnancy category is not established. Clinicians should weigh potential benefits against unknown risks, and breastfeeding mothers should consult a healthcare professional before use.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Metronidazole is a first‑line nitroimidazole with excellent activity against most anaerobic bacteria and certain protozoa. Compared with broad‑spectrum agents like clindamycin or carbapenems, it offers a narrower spectrum, lower cost, and fewer drug‑resistance concerns, but it lacks activity against aerobic organisms.

Metronidazol B. Braun should be stored refrigerated at 2‑8 °C. Keep the vial in its original packaging, protect it from light, and do not freeze or shake the solution. If a temporary temperature excursion occurs, consult the supplier before use.

The product is supplied as an injectable solution for intravenous infusion. It is administered by a qualified healthcare professional, typically diluted in compatible IV fluids and infused over a period determined by the prescriber, based on infection severity and patient tolerance.

Serious adverse events include seizures, peripheral neuropathy, severe allergic reactions (including anaphylaxis), Stevens‑Johnson syndrome, hepatic dysfunction, and pancytopenia. Patients should be monitored for neurological changes, skin reactions, and liver function abnormalities during therapy.

Metronidazol B. Braun is contraindicated in patients with a known hypersensitivity to metronidazole or other nitroimidazoles. Caution is advised in individuals with severe hepatic impairment, early pregnancy, or those taking disulfiram‑like medications, unless the prescribing clinician determines that benefits outweigh risks.